27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Parkinson's disease, as well as other neurodegenerative disorders, are primarily characterized by pathological accumulation of proteins, inflammation, and neuron loss. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The pro-inflammatory activation of microglia is a hallmark of Alzheimer's disease (AD), and this process involves a switch from oxidative phosphorylation (OXPHOS) toward glycolysis. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
These findings support that a complex gut microbiome is required for behavioural defects, microglia activation and AD pathologies, the gut microbiome contributes to pathologies in an AD mouse model and that dysbiosis of the human microbiome might be a risk factor for AD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The human body is full of an extensive number of commensal microbes, consisting of bacteria, viruses, and fungi, collectively termed the human microbiome. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Gut microbiota alterations might affect the development of Alzheimer's disease (AD) through microbiota-derived metabolites. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The intestinal barrier, which primarily consists of a mucus layer, an epithelial barrier, and a gut vascular barrier, has a crucial role in health and disease by facilitating nutrient absorption and preventing the entry of pathogens. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
As the number of patients with Alzheimer's disease (AD) increases, it brings great suffering to their families and causes a heavy socioeconomic burden to society. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Traditionally, lymphocytic interferon γ (IFN-γ) was considered to be a simple 'booster' of proinflammatory responses by microglia (brain-resident macrophages) during bacterial or viral infection. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Spatial molecular profiling of complex tissues is essential to investigate cellular function in physiological and pathological states. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Microglia are critical in brain development and Alzheimer's disease (AD) etiology. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the most common form of dementia in the elderly, and there are still no reliable methods for its early detection. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Food and Drug Administration-s (FDA) approval of aducanumab (Aduhelm® in the US) as a treatment for mild cognitive impairment of the Alzheimer type and Alzheimer-s disease has raised such major concerns about efficacy, safety, FDA processes, and regulatory capture that Biogen-s license to market this biologic should be immediately withdrawn. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Each year’s cognitive functions were linked to the prior year’s food insecurity values. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 11 case reports met criteria for inclusion. 5 key findings →
Design: cross-sectional Participants: 56 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Very early in the course of the Covid-19 pandemic, it became glaringly clear that older persons were at significantly increased risk of infection, severe illness, hospitalization, intensive care and respiratory support, and death. 5 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We found notable differences in socio‐demographic and clinical characteristics, and utilization patterns in the year prior to death between decedents with dementia who were hospitalized in the last 30 days of life vs. those who were not. 4 key findings →
Participants: 6,299 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The pathology of Alzheimer’s disease (AD), the most common cause of dementia, is considered to be mainly driven by two major hallmarks (tau and amyloid beta). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The uptake of 18 F‐PI‐2620 was distinctly increased in the AD group across all the ROIs. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Blood phospho-tau181 may offer a useful biomarker for Alzheimer’s disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Three new drugs are presented: dostarlimab, loncastuximab tesirine, and aducanumab. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A person affected by Alzheimer's disease (AD) gradually loses the ability to perform activities of daily living and becomes dependent on caregivers, thereby having a negative impact on the caregivers' quality of life. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Most Alzheimer disease (AD) patients present as sporadic late onset AD, with metabolic factors playing an important role in the occurrence and development of AD. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Deep-learning methods (especially convolutional neural networks) using structural magnetic resonance imaging (sMRI) data have been successfully applied to computer-aided diagnosis (CAD) of Alzheimer's disease (AD) and its prodromal stage [i.e., mild cognitive impairment (MCI)]. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The results of anonymous surveys conducted among the clinic9s providers are reported as descriptive findings. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Home-based medical care (HBMC) delivers physician or advanced practice provider-led medical services for patients in private residences and domiciliary settings (eg, assisted living facilities, group/boarding homes). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →